Study guide

8.1 Therapeutic Radiopharmaceuticals

Certified Nuclear Medicine Technologist CNMT

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current CNMT Exam Facts 1.2 How to Use This Guide

2 Radiation Physics Fundamentals

2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles

3 Biological Effects & ALARA

3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring

4 NRC & Regulatory Compliance

4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records

5 Generators & Kit Preparation

5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control

6 Tc-99m Diagnostic Agents

6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells

7 Non-Tc Diagnostic & PET Agents

7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents

8 Therapeutics, Adjuncts & Administration

8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents

9 Non-Imaging Instrumentation

9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment

10 Imaging Systems & Quality Control

10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization

11 Pulmonary, Bone, Oncology & Infection Imaging

11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures

12 Renal, Endocrine & Hematopoietic Imaging

12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique

13 Cardiovascular Procedures

13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing

14 GI, CNS, Therapy & Hybrid CT Procedures

14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency

15 Patient Care & Clinical Workflow

15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis

8.1 Therapeutic Radiopharmaceuticals

Key Takeaways Explain This Topic AI

I-131 NaI treats hyperthyroidism (typically lower mCi activities) and thyroid cancer remnant/metastatic disease (higher ablation activities); release hinges on NRC patient-release criteria, not a single fixed mCi cutoff alone

Lu-177 dotatate (Lutathera®) is PRRT for SSTR-positive GEP-NETs; co-infuse amino acids for renal protection and monitor marrow toxicity

Lu-177 vipivotide tetraxetan (Pluvicto®) targets PSMA-positive mCRPC; Ra-223 (Xofigo®) is an alpha bone-seeking agent for symptomatic bone mets without visceral disease

Sr-89 (Metastron®) palliates painful osteoblastic mets with beta emission and notable myelosuppression risk

Y-90 microspheres (SIR-Spheres® resin, TheraSphere® glass) deliver liver-directed beta therapy after MAA mapping; written directives and radiation-safety handling apply

Last updated: August 2026

8.1 Therapeutic Radiopharmaceuticals

Quick Answer: Therapy agents deliver beta or alpha dose at disease sites. I-131 NaI → hyperthyroid and thyroid-cancer ablation with release criteria and isolation teaching. Lu-177 products (Lutathera®, Pluvicto®) → SSTR/PSMA targets plus renal amino acids (Lutathera) and CBC monitoring . Ra-223 (alpha bone) and Sr-89 (beta bone palliation) vs Y-90 microspheres for hepatic radioembolization.

Therapeutic RPs deposit beta or alpha energy at disease targets while non-target organs set toxicity limits. Exam items pair indication → nuclide/chemistry → special handling → monitoring .

I-131 Sodium Iodide: Hyperthyroidism and Ablation

I-131 decays by beta emission (therapeutic local dose) plus 364 keV gamma (imaging/surveys). Oral NaI is trapped and organified in functioning thyroid tissue and differentiated thyroid cancer that retains NIS activity.

Clinical goal Typical activity concept (adult order-of-magnitude) Notes

Hyperthyroidism (Graves, toxic nodule/goiter) Often ~4–30 mCi (method- and gland-dependent) Calculated vs fixed-dose; higher uptake may lower activity

Remnant ablation / adjuvant after thyroidectomy Commonly tens of mCi (e.g., ~30–100 mCi classically discussed) Risk stratification drives written directive

Known/metastatic DTC Often higher activities (e.g., 100–200 mCi range historically taught) Inpatient vs outpatient depends on release rules

Know hyperthyroid ≪ cancer ablation and that written directives are required under NRC 10 CFR Part 35. Pregnancy is an absolute contraindication; document pregnancy testing per policy. Breastfeeding must stop. Recent iodinated contrast, amiodarone, or excess stable iodine can block uptake. Low-iodine diet and TSH elevation (withdrawal or rhTSH/Thyrogen® ) apply mainly to cancer pathways.

Release Criteria Concepts (High-Yield)

NRC §35.75 allows release if the TEDE to any other individual is not likely to exceed 5 mSv (0.5 rem) . Licensees may use default activity/dose-rate tables, patient-specific calculations, and/or measured dose rate (commonly discussed ≤0.07 mSv/h (7 mrem/h) at 1 m for I-131). Release is risk-based , not a single universal mCi lockout. Provide written instructions (sleep apart, bathroom hygiene, time/distance limits).

Major excretion is urine —private toilet teaching, contamination control for vomitus, and room/waste surveys per license. High-activity inpatients need time-distance-shielding plans and defined visitor/staff stay triggers.

Lu-177 Dotatate (Lutathera®) — PRRT for NETs

Lutetium-177 emits beta particles (therapy) and low-abundance gammas useful for post-therapy imaging. Dotatate targets somatostatin receptor subtype 2 (SSTR2) on well-differentiated GEP-NETs (and related SSTR-positive disease per labeling/indication).

  • Item Teaching point
  • Typical regimen 7.4 GBq (200 mCi) IV every ~8 weeks × 4 doses (label-style)

Amino acid co-infusion Lysine/arginine (or approved AA solution) before/during/after to reduce proximal tubular reuptake and renal dose

  • Antiemetics Often needed (AA infusion and disease-related nausea)
  • Monitoring CBC (myelosuppression), renal function, liver tests; delay/hold for severe cytopenias

Contraindications / cautions Severe renal impairment, pregnancy, uncontrolled infection, severe marrow compromise—follow label and authorized user

Cold SSA timing is coordinated so receptors remain available. Do not confuse with Pluvicto: both are Lu-177 but targets and co-meds differ (AA co-infusion is a Lutathera hallmark).

Lu-177 Vipivotide Tetraxetan (Pluvicto®) — PSMA Prostate Cancer

Pluvicto® binds PSMA on prostate cancer cells for PSMA-positive mCRPC after appropriate prior therapy per labeling.

  • Item Teaching point
  • Activity concept 7.4 GBq (200 mCi) IV every ~6 weeks , up to 6 doses if tolerating
  • Key toxicities Myelosuppression , dry mouth (salivary PSMA), nausea, fatigue, renal caution
  • Safety Lu-177 handling; written directive; post-void/hygiene teaching (renal excretion)
  • Ra-223 Dichloride (Xofigo®)

Radium-223 is an alpha emitter that behaves like calcium , localizing in bone mineral at sites of osteoblastic turnover.

  • Item Teaching point
  • Indication CRPC with symptomatic bone metastases and no visceral metastatic disease (classic label concept)
  • Dose 55 kBq/kg (1.49 µCi/kg) IV every 4 weeks × 6
  • Advantage High LET alpha; short range; CBC monitoring still required
  • Handling Alpha precautions; blood/urine contamination control
  • Sr-89 Chloride (Metastron®)

Strontium-89 is a beta emitter and calcium analog for painful osteoblastic metastases (palliation, not soft-tissue disease control).

  • Item Teaching point
  • Activity Often 148 MBq (4 mCi) or ~1.5–2.2 MBq/kg
  • Toxicity Significant myelosuppression ; nadir weeks later; avoid if marrow critically low
  • Clinical use Bone pain relief; may flare pain early; longer half-life than Sm-153 on comparison items
  • Y-90 Microspheres: SIR-Spheres® and TheraSphere®

Yttrium-90 pure beta therapy in microspheres for SIRT/TARE of hepatic malignancy via hepatic arterial infusion.

  • Product concept Carrier Teaching contrast
  • SIR-Spheres® Resin microspheres More embolic particle load concept
  • TheraSphere® Glass microspheres Higher specific activity per sphere

Workflow: angiographic mapping + Tc-99m MAA (lung shunt, extrahepatic flow) → written directive → IR catheter delivery with residual activity assay and surveys. Contraindications include excessive hepatopulmonary shunt , uncorrectable extrahepatic deposition, and inadequate liver reserve. Y-90 has minimal gammas; post-therapy imaging is specialized (bremsstrahlung/PET), not an I-131 whole-body analog.

Cross-Cutting Therapy Safety

  • Theme Apply to
  • Written directive All Part 35 therapeutic administrations
  • Myelosuppression labs Lu-177 agents, Ra-223, Sr-89, high-dose I-131
  • Renal protection Amino acids with Lutathera ; hydration teaching broadly
  • Identity + activity assay Dual verification before administration
  • Contamination control Body fluids (I-131, Lu-177, Sr-89, Ra-223)

Selection map: thyroid tissue → I-131 ; SSTR NET → Lutathera ; PSMA mCRPC → Pluvicto ; symptomatic bone mets (alpha, no visceral) → Ra-223 ; beta bone palliation → Sr-89 ; liver-dominant arterial therapy → Y-90 microspheres . If an item names a commercial brand, map it to the nuclide and target first—then recall dose concept, co-meds, and the dominant toxicity (marrow, kidney, or liver reserve).